石藥(01093.HK)受制百天線倒跌12%失15元 獲利盤湧現
建議於滬科創板上市的石藥集團(01093.HK)首季多賺近22%大行績後維持看好,但公司指受累於新冠肺炎疫情影響,期內銷售收入及核心利潤增長均低於預期。該股承過去三連漲勢,今早逆市高開見17.12元遇阻,未能企穩百天線(17.03元),獲利盤湧現,股價掉頭一舉跌破20天、50天、10天及牛熊線(15.62-16.23元),最低見14.82元,現造14.9元,急吐12%,為最傷藍籌,成交達6,879萬股,已接近昨天全日成交量7,938萬股。
石藥昨午公布,首季純利按年升21.8%至11.59億元人民幣(下同),毛利按年升近18%至45.29億。期內,總營收按年升11.5%至61.25億元,其中成藥收入按年升18.3%至50.22億元。里昂及瑞信績後重申「買入」及「跑贏大市」評級,分別看20.46元及19.88元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.